miércoles, 10 de julio de 2013

WHO Pharmaceuticals Newsletter No.3, 2013


Contenidos


Asuntos regulatorios

Azithromycin ............................................................................... 4

Cilostazol-containing medicines .......................................................... 4

Denosumab .................................................................................. 4

Lapatinib ditosylate ........................................................................5

Proton pump inhibitors.....................................................................5

Strontium ranelate ..........................................................................6

Tetrazepam-containing medicines ........................................................6

Thalidomide ..................................................................................7

Tolvaptan ......................................................................................7

Valproate sodium, divalproex sodium, valproic acid ................................... 8

Seguridad de medicamentos 

Ado-trastuzumab emtansine ................................................................ 9

Aqueous cream ............................................................................... 9

Bevacizumab .................................................................................. 9

Botulinum toxin type B .......................................................................10

Domperidone-containing medicines ....................................................... 10

Ezogabine ..................................................................................... 10

Flupirtine-containing medicines ............................................................ 11

Insulin degludec ............................................................................... 11

Montelukast .................................................................................... 12

Nicotinic acid, acipimox and xantinol nicotinate ......................................... 12

Nilotinib ........................................................................................ 12


Signal

Fluoxetine and Deafness ......................................................................... 14




disponible en
http://bit.ly/1av3oKU